ErbB2/Her2 Antikörper (AA 151-250)
Kurzübersicht für ErbB2/Her2 Antikörper (AA 151-250) (ABIN678068)
Target
Alle ErbB2/Her2 Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
- 
    - 
                                            Bindungsspezifität
- AA 151-250
- 
                                            Kreuzreaktivität
- Human, Ratte
- 
                                            Homologie
- Dog,Horse
- 
                                            Aufreinigung
- Purified by Protein A.
- 
                                            Immunogen
- KLH conjugated synthetic peptide derived from human ErbB2
- 
                                            Isotyp
- IgG
 
- 
                                            
- 
    
- 
    - 
                                            Applikationshinweise
- 
                        ELISA 1:500-1000
 FCM 1:20-100
 IHC-P 1:200-400
 IHC-F 1:100-500
 IF(IHC-P) 1:50-200
 IF(IHC-F) 1:50-200
 IF(ICC) 1:50-200
 ICC 1:100-500
- 
                                            Beschränkungen
- Nur für Forschungszwecke einsetzbar
 
- 
                                            
- 
    - 
                                            Format
- Liquid
- 
                                            Konzentration
- 1 μg/μL
- 
                                            Buffer
- 0.01M TBS( pH 7.4) with 1 % BSA, 0.02 % Proclin300 and 50 % Glycerol.
- 
                                            Konservierungsmittel
- ProClin
- 
                                            Vorsichtsmaßnahmen
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
- 
                                            Lagerung
- 4 °C,-20 °C
- 
                                            Informationen zur Lagerung
- Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.
- 
                                            Haltbarkeit
- 12 months
 
- 
                                            
- 
    - ErbB2/Her2 (Receptor tyrosine-protein kinase erbB-2 (ErbB2/Her2))
- 
                                            Andere Bezeichnung
- ErbB2
- 
                                            Hintergrund
- 
                        Synonyms: NEU, NGL, HER2, TKR1, CD340, HER-2, MLN 19, HER-2/neu, Receptor tyrosine-protein kinase erbB-2, Metastatic lymph node gene 19 protein, Proto-oncogene Neu, Proto-oncogene c-ErbB-2, Tyrosine kinase-type cell surface receptor HER2, p185erbB2, ERBB2, MLN19 Background: Protein tyrosine kinase that is part of several cell surface receptor complexes, but that apparently needs a coreceptor for ligand binding. Essential component of a neuregulin-receptor complex, although neuregulins do not interact with it alone. GP30 is a potential ligand for this receptor. Regulates outgrowth and stabilization of peripheral microtubules (MTs). Upon ERBB2 activation, the MEMO1-RHOA-DIAPH1 signaling pathway elicits the phosphorylation and thus the inhibition of GSK3B at cell membrane. This prevents the phosphorylation of APC and CLASP2, allowing its association with the cell membrane. In turn, membrane-bound APC allows the localization of MACF1 to the cell membrane, which is required for microtubule capture and stabilization. In the nucleus is involved in transcriptional regulation. Associates with the 5'-TCAAATTC-3' sequence in the PTGS2/COX-2 promoter and activates its transcription. Implicated in transcriptional activation of CDKN1A, the function involves STAT3 and SRC. Involved in the transcription of rRNA genes by RNA Pol I and enhances protein synthesis and cell growth. 
- 
                                            Gen-ID
- 2064
- 
                                            UniProt
- P04626
- 
                                            Pathways
- RTK Signalweg, Fc-epsilon Rezeptor Signalübertragung, EGFR Signaling Pathway, Neurotrophin Signalübertragung, Skeletal Muscle Fiber Development
 Target
- 
                    
 
                                     
                                     
                                    